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Small molecule binding at the Src SH2 domain
A variety of proteins involved in signal transduction contain non-catalytic Src homology-2
(SH2) domains that function as mediators of intracellular protein-protein interactions. These
SH2 domains (~100 amino acids in size) bind pTyr-containing proteins and peptides in a
sequence dependent manner, which provides on a cellular level the basis for differentiation of
the phosphorylation/dephosphorylation events surrounding a multitude of signalling pathways.
This intricate role of SH2 domains in cell function coupled with the postulated involvement of
the nonreceptor tyrosine kinase Src in various disease states, such as cancer and osteoporosis,
provides an impetus to develop Src SH2-binding small molecules as therapeutic modulators of
the aberrant signalling activity associated with these diseases. A solid-phase parallel approach
in combination with molecular modelling was used to guide the design and synthesis of library
of Src SH2 domain inhibitors (Structure-based design and solid-phase parallel synthesis of
phosphorylated nonpeptides to explore hydrophobic binding at the Src SH2 domain, C. A.
Metcalf III et. al., J. Comb. Chem., 2, (2000), 305-313). A library of individual compounds
was synthesised on Rink amide AM resin. One of the most potent and selective compounds
identified was (i) which bound to Src SH2 with an IC50 of 900 nM. This approach has
demonstrated the successful marrying of solid-phase parallel synthesis and structure-based
methods to explore binding of small molecules to the Src SH2 domain with a series of
phosphorylated nonpeptides. These techniques may again prove useful in designing and
synthesising future libraries of novel Src SH2 inhibitors which seek to address cell potency and
selectivity issues.
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Inhibition of galactose-binding proteins
Despite a growing appreciation of the importance of complex carbohydrates in medicinally
relevant receptor-ligand interactions, few carbohydrate-based drugs have reached the market.
This is due in part to the polar and hydrolytically labile nature of carbohydrates, as well as the
fact that monovalent interactions between carbohydrates and proteins are often low affinity.
Nature usually employs polyvalency to ensure high affinity. A solution-phase parallel approach
has been used to discover small molecules inhibiting β-galactosidase from E. coli. (Parallel
solution synthesis of a 'carbohybrid' library designed to inhibit galactose-binding proteins, O.
Hindsgaul, et. al., Comb. Chem. High Throughput Screen., 2, (1999), 335-352). A library of
360 individual compounds was synthesised by alkylation of a galactopyranose followed by
either reductive amination of a ketone functionality and acylation of the resultant amine, or
reduction of the ketone to an alcohol. One of the most potent compounds prepared from this
library was (ii), with a minimum inhibitory concentration of 76 µM for hemagglutination
inhibition against Abrus precatorius toxin A. This type of approach could be useful in
delivering small 'key sugar'-based 'carbohybrids' (pyranosides carrying structurally diverse
aglycons) with high affinity for proteins, thereby efficiently inhibiting polyvalent carbohydrate-
protein interactions, entities which may prove attractive starting points for therapeutic
development.
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